The on-site negotiation and bidding processes for the 2023 update to China’s National Reimbursement Drug List (NRDL) commenced on November 17, 2023, and concluded on November 20, lasting a total of four days. The National Healthcare and Security Administration (NHSA) selected 25 experts to carry out the negotiations, which were divided among five different groups.
Drugs Impacted and Process Details
A total of 168 drugs are subject to these negotiations and bidding, comprising 148 negotiation drugs and 20 non-exclusive drugs entering the bidding process. These numbers were narrowed down from an initial pool of 41 drugs eligible for price bidding and 170 western medicines eligible for exclusive negotiations. Additionally, 121 western medicines were scheduled for NRDL contract renewals.
Implementation of Results
The outcomes of these negotiations and bidding processes, anticipated to be published in the following month, are set to take effect from January 1, 2024, impacting the accessibility and affordability of these medicines for patients across the country.- Flcube.com
